Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-3505 in ALK-Positive Advanced NSCLC
NCT05869162Phase 2Unknown
- Sponsor
- Shouyao Holdings
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ficonalkib in non-small cell lung cancer (NSCLC), sponsored by Shouyao Holdings. Status: unknown.
02
Drugs
ficonalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05869162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869162.